EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 43 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 63 cases where EDIT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 224 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 46 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.501) is normal, around the industry mean (3.035). P/E Ratio (-3.636) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ONCY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 47 cases where ONCY's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 81%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ONCY's RSI Oscillator exited the oversold zone, 32 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 64 cases where ONCY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for ONCY just turned positive on October 22, 2026. Looking at past instances where ONCY's MACD turned positive, the stock continued to rise in 31 of 47 cases over the following month. The odds of a continued upward trend are 66%.
Following a +3.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where ONCY advanced for three days, in 147 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ONCY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ONCY entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-10.386) is normal, around the industry mean (3.035). P/E Ratio (-1.435) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. ONCY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ONCY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EDIT | ONCY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 48 Fair valued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 74 | 88 | |
P/E GROWTH RATING 1..100 | 23 | 12 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ONCY's Valuation (12) in the Biotechnology industry is somewhat better than the same rating for EDIT (48). This means that ONCY’s stock grew somewhat faster than EDIT’s over the last 12 months.
ONCY's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that ONCY’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's SMR Rating (99) in the Biotechnology industry is in the same range as ONCY (100). This means that EDIT’s stock grew similarly to ONCY’s over the last 12 months.
EDIT's Price Growth Rating (74) in the Biotechnology industry is in the same range as ONCY (88). This means that EDIT’s stock grew similarly to ONCY’s over the last 12 months.
ONCY's P/E Growth Rating (12) in the Biotechnology industry is in the same range as EDIT (23). This means that ONCY’s stock grew similarly to EDIT’s over the last 12 months.
| EDIT | ONCY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 76% |
| Stochastic ODDS (%) | 2 days ago 79% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 90% | N/A |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 81% | 2 days ago 74% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 80% | 4 days ago 76% |
| Declines ODDS (%) | 2 days ago 90% | 6 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 86% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while ONCY’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while ONCY’s TA Score has 5 bullish TA indicator(s).
EDIT (@Biotechnology) experienced а +2.13% price change this week, while ONCY (@Biotechnology) price change was +0.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
EDIT is expected to report earnings on Nov 09, 2026.
ONCY is expected to report earnings on Nov 11, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| LABD | 7.96 | 0.34 | +4.46% |
| Direxion Daily S&P Biotech Bear 3X ETF (LABD) | |||
| XTAP | 46.97 | N/A | N/A |
| Innovator U.S. Equity Accelerated Plus ETF (XTAP) | |||
| TMB | 24.92 | N/A | N/A |
| Thornburg Multi Sector Bond ETF (TMB) | |||
| ZIL.X | 0.002004 | -0.000076 | -3.63% |
| Zilliqa cryptocurrency | |||
| BAT.X | 0.158533 | -0.009350 | -5.57% |
| Basic Attention Token cryptocurrency | |||
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -3.61% | ||
| BEAM - EDIT | 66% Closely correlated | -2.08% | ||
| CRSP - EDIT | 63% Loosely correlated | -1.20% | ||
| PRME - EDIT | 61% Loosely correlated | -1.61% | ||
| SLDB - EDIT | 60% Loosely correlated | -4.36% | ||
| VYGR - EDIT | 59% Loosely correlated | -6.45% | ||
More | ||||